Answers are grounded in this paper and cite their sources.
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, a phase 3 trial showed that the BCMA‐targeting bispecific antibody teclistamab significantly improved progression‐free survival and overall survival in patients with relapsed or refractory multiple myeloma who received one to three previous lines of therapy. In addition, adjuvant nivolumab fails to improve disease‐free survival in patients with resected NSCLC, and perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer.
No takes yet. Share an insight, caveat, or question.
Leah Lawrence (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: